Early investigational TNF receptor antagonists for the treatment of ulcerative colitis

Bibliography

• Gearry RB, Richardson A, Frampton CMA, et al. High incidence of Crohn’s disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis 2006;12(10):936-43
   PubMed Web of Science ®Google Scholar
• Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn’s disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet 2001;10:445-56
   PubMed Web of Science ®Google Scholar
• Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet 2010;42:1118-25
   PubMed Web of Science ®Google Scholar
• Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43(3):246-52
   PubMed Web of Science ®Google Scholar
• Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology 2005;128:2020-8
   PubMed Web of Science ®Google Scholar
• Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000;47:487-96
   PubMed Web of Science ®Google Scholar
• Lawrance IC, Hall A, Leong R, et al. A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD. Inflamm Bowel Dis 2005;11:890-7
   PubMed Web of Science ®Google Scholar
• Lawrance IC, Murray K, Hall A, et al. A prospective comparative study of ASCA and pANCA in Chinese and caucasian IBD patients. Am J Gastroenterol 2004;99:2186-94
   PubMed Web of Science ®Google Scholar
• Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis 2002;8:244-50
   PubMed Web of Science ®Google Scholar
• Lakatos PL, Czegledi Z, Szamosi T, et al. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn’s disease. World J Gastroenterol 2009;15:3504-10
   PubMed Web of Science ®Google Scholar
• Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521-33
   PubMed Web of Science ®Google Scholar
• Kennedy RJ, Hoper M, Deodhar K, et al. Interleukin 10-deficient colitis: new similarities to human inflammatory bowel disease. Br J Surg 2000;87:1346-51
   PubMed Web of Science ®Google Scholar
• Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001;411:599-603
   PubMed Web of Science ®Google Scholar
• Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 2001;411:603-6
   PubMed Web of Science ®Google Scholar
• Cohen RD, Kirsner JB, Ekbom A, et al. Inflammatory bowel disease: diagnosis and therapeutics. Springer Science+Business Media; New York, NY 10013, USA: LLC 2011
   Google Scholar
• Wills-Karp M, Santeliz J, Karp CL. The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat Rev Immunol 2001;1:69-75
   PubMed Web of Science ®Google Scholar
• Sudo N, Sawamura S, Tanaka K, et al. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. J Immunol 1997;159:1739-45
   PubMed Web of Science ®Google Scholar
• Fowler EV, Doecke J, Simms LA, et al. ATG16L1 T300A shows strong associations with disease subgroups in a large Australian IBD population: further support for significant disease heterogeneity. Am J Gastroenterol 2008;103:2519-26
   PubMed Web of Science ®Google Scholar
• Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol 1993;94:174-81
   PubMed Web of Science ®Google Scholar
• Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-17
   PubMed Web of Science ®Google Scholar
• Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn’s disease. Lancet 1999;353:459-61
   PubMed Web of Science ®Google Scholar
• Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91
   PubMed Web of Science ®Google Scholar
• MacDonald TT, Hutchings P, Choy MY, et al. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol 1990;81:301-5
   PubMed Web of Science ®Google Scholar
• Broomé U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis 2006;26:31-41
   PubMed Web of Science ®Google Scholar
• Arora G, Singh G, Vadhavkar S, et al. Incidence and risk of intestinal and extra-intestinal complications in Medicaid patients with inflammatory bowel disease: a 5-year population-based study. Dig Dis Sci 2010;55:1689-95
   PubMed Web of Science ®Google Scholar
• Lawrance IC. Infliximab in the management of the extra-intestinal manifestations of Crohn’s disease. J Gastroenterol Hepatol 2004;19:1332-3
   PubMed Web of Science ®Google Scholar
• Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;1:1067-70
   PubMed Web of Science ®Google Scholar
• Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005-13
   PubMed Web of Science ®Google Scholar
• Faubion WAJr, Loftus EVJr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. see comment Gastroenterology 2001;121:255-60
   PubMed Web of Science ®Google Scholar
• Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5
   PubMed Web of Science ®Google Scholar
• Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005;17:79-84
   PubMed Web of Science ®Google Scholar
• Arts J, D’Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004;10:73-8
   PubMed Web of Science ®Google Scholar
• Moskovitz DN, Van Assche G, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006;4:760-5
   PubMed Web of Science ®Google Scholar
• Durai D, Hawthorne AB. Review article: how and when to use ciclosporin in ulcerative colitis. Aliment Pharmacol Ther 2005;22:907-16
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Assche G, Vermeire S. Anti-TNF Treatment in Inflammatory Bowel Disease. Gastroenterology 2004;126:1593-610
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007;13:1323-32
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen A, Kaser A. Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases. Expert Opin Biol Ther 2007;7:1051-9
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94
   PubMed Web of Science ®Google Scholar
• Murch SH, Braegger CP, Walker-Smith JA, et al. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34:1705-9
   PubMed Web of Science ®Google Scholar
• Chey WY, Hussain A, Ryan C, et al. Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001;96:2373-81
   PubMed Web of Science ®Google Scholar
• Kaser A, Mairinger T, Vogel W, et al. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr 2001;113:930-3
   PubMed Web of Science ®Google Scholar
• Actis GC, Bruno M, Pinna-Pintor M, et al. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis 2002;34:631-4
   PubMedGoogle Scholar
• Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001;7:83-8
   PubMed Web of Science ®Google Scholar
• Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003;52:998-1002
   PubMed Web of Science ®Google Scholar
• Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan B, Olson A, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007;25:19-37
   PubMed Web of Science ®Google Scholar
• Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis 2010;4:431-7
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250-60; quiz 1520
   PubMed Web of Science ®Google Scholar
• Croft A, Walsh A, Doecke J, et al. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol Ther 2013;38:294-302
   PubMed Web of Science ®Google Scholar
• Kim EH, Kim DH, Park SJ, et al. Infliximab versus cyclosporine treatment for severe corticosteroid-refractory ulcerative colitis: a korean, retrospective, single center study. Gut Liver 2014. [Epub ahead of print]
   Google Scholar
• Molnar T, Farkas K, Szepes Z, et al. Long-term outcome of cyclosporin rescue therapy in acute, steroid-refractory severe ulcerative colitis. United European Gastroenterol J 2014;2:108-12
   Google Scholar
• Naves JE, Llao J, Ruiz-Cerulla A, et al. Long-term comparative efficacy of cyclosporine- or infliximab-based strategies for the management of steroid-refractory ulcerative colitis attacks. Inflamm Bowel Dis 2014;20:1375-81
   PubMed Web of Science ®Google Scholar
• Chang KH, Burke JP, Coffey JC. Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis. Int J Colorectal Dis 2013;28:287-93
   PubMed Web of Science ®Google Scholar
• Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012;380:1909-15
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Motoya S, Hanai H, et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol 2014;49:283-94
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Panaccione R, et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis 2013;19:1700-9
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Ghosh S, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3. Am J Gastroenterol 2014;109:1771-80
   PubMed Web of Science ®Google Scholar
• Wolf D, D’Haens G, Sandborn WJ, et al. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther 2014;40:486-97
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007;357:228-38
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007;357:239-50
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Thomsen OO, Schreiber S, et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn’s disease for up to 18 months. Clin Gastroenterol Hepatol 2010;8:600-9
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Schreiber S, Hanauer SB, et al. Reinduction with certolizumab pegol in patients with relapsed Crohn’s disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol 2010;8:696-702; e1
   PubMed Web of Science ®Google Scholar
• Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2014;39:447-58
   PubMed Web of Science ®Google Scholar
• Mozaffari S, Nikfar S, Abdolghaffari AH, et al. New biologic therapeutics for ulcerative colitis and Crohn’s disease. Expert Opin Biol Ther 2014;14:583-600
   PubMed Web of Science ®Google Scholar
• Hiroz P, Vavricka SR, Fournier N, et al. Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss inflammatory bowel disease cohort. Scand J Gastroenterol 2014;49:1207-18
   PubMed Web of Science ®Google Scholar
• Ishida I, Tomizuka K, Yoshida H, et al. Production of human monoclonal and polyclonal antibodies in TransChromo animals. Cloning Stem Cells 2002;4:91-102
   PubMedGoogle Scholar
• Shealy DJ, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs 2010;2:428-39
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:85-95; quiz e14-5
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014;146:96-109; e1
   PubMed Web of Science ®Google Scholar
• Lawrance IC, Radford-Smith GL, Bampton PA, et al. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol 2011;25:1732-8
   Web of Science ®Google Scholar
• Mill J, Lawrance IC. Preventing infective complications in inflammatory bowel disease. World J Gastroenterol 2014;20:9691-8
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Cheifetz AS. Miscellaneous adverse events with biologic agents (excludes infection and malignancy). Gastroenterol Clin North Am 2014;43:543-63
   PubMed Web of Science ®Google Scholar
• Marzano AV, Borghi A, Meroni PL, et al. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy. Autoimmunity 2014;47:146-53
   PubMed Web of Science ®Google Scholar
• Targownik LE, Bernstein CN. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol 2013;108:1835-42; quiz 1843
   PubMed Web of Science ®Google Scholar
• Lawrance IC, Copeland TS. Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther 2008;28:1214-20
   PubMed Web of Science ®Google Scholar
• Tan T, Lawrance IC. Use of mycophenolate mofetil in inflammatory bowel disease. World J Gastroenterol 2009;15:1594-9
   PubMed Web of Science ®Google Scholar
• Thin LW, Murray K, Lawrance IC. Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era. Inflamm Bowel Dis 2013;19:1490-8
   PubMed Web of Science ®Google Scholar
• Waters OR, Lawrance IC. Understanding the use of immunosuppressive agents in the clinical management of IBD. Curr Drug Targets 2011;12:1364-71
   PubMed Web of Science ®Google Scholar
• Lawrance IC. What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails? World J Gastroenterol 2014;20:1248-58
   PubMed Web of Science ®Google Scholar
• Chew A, Tulic M, Mallon D, et al. Dysregulation of innate immune signalling in ulcerative colitis. JCC 2012;6:S128
   Google Scholar
• Gibson DJ, Heetun ZS, Redmond CE, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar